Study on the relationship between the changes of microbiota and therapeutic effect in patients with reflux esophagitis

doi:10.3969/j.issn.1006-7795.2020.02.016

Abstract

Abstract: Objective To study the relationship between the changes of lower esophageal mucosal microbiota and the therapeutic effect in the patients with reflux esophagitis. Methods The patients with reflux esophagitis were recruited and undertook standard proton pump inhibitor (PPI) therapy for 8 weeks. They were divided into mucosal healing group and poor healing group. The high-throughput nucleotide sequencing and bioinformatics analysis techniques were used to analyze the composition of the distal esophageal mucosal microbiota in the reflux esophagitis before and after PPI therapy. Results In the healing group, there were significant differences on the abundances of the lower esophageal mucosa between before and after PPI therapy at the level of genus:Lactobacillaceae, Lactobacillus, Bifidobacterium and Helicobacter [2.7%(1.5%-3.2%) vs 4.8%(3.0%-10.7%), 2.7%(1.5%-3.2%) vs 4.8%(3.0%-10.7%), 0.7%(0.6%-10.7%) vs 1.4%(1.0%-2.2%), 0.08%(0.04%-0.13%) vs 0.12%(0.08%-0.21%)](P=0.001, P=0.001, P=0.042, P=0.049, respectively). The abundances of Bifidobacterium and Helicobacter at the level of genus in the healing group after the PPI therapy were significant increasing than those in the poor healing group[1.4%(1.0%-2.2%) vs 0.7%(0.4%-1.1%), 0.12%(0.08%-0.21%) vs 0.07%(0.03%-0.09%)] (P=0.003, P=0.014). Conclusion The changes in the lower esophageal mucosal microbiota after PPI therapy in patients with reflux esophagitis are related to the therapeutic effect. And in the healing group, the proportion of beneficial bacteria significantly increased.

Key words: reflux esophagitis, high-throughput DNA sequencing, microbiota, therapeutic effect

CLC Number:

Yu Ying, Gao Feng, Zhang Jie. Study on the relationship between the changes of microbiota and therapeutic effect in patients with reflux esophagitis[J]. Journal of Capital Medical University, 2020, 41(2): 243-248.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.02.016

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I2/243

References

[1] Ley R E, Peterson D A, Gordon J I. Ecological and evolutionary forces shaping microbial diversity in the human intestine[J]. Cell, 2006, 124(4):837-848.
[2] DiBaise J K, Zhang H, Crowell M D, et al. Gut microbiota and its possible relationship with obesity[J].Mayo Clin Proc, 2008, 83(4):460-469.
[3] Di Pilato V, Freschi G, Ringressi M N, et al. The esophageal microbiota in health and disease[J]. Ann NY Acad Sci, 2016, 1381(1):21-33.
[4] Blackett K L, Siddhi S S, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma:association or causality?[J]. Aliment Pharmacol Ther, 2013, 37(11):1084-1092.
[5] Wang Z K, Yang Y S. Upper gastrointestinal microbiota and digestive diseases[J]. World J Gastroenterol, 2013, 19(10):1541-1550.
[6] Hunt R H, Yaghoobi M. The esophageal and gastric microbiome in health and disease[J]. Gastroenterol Clin North Am, 2017, 46(1):121-141.
[7] Corning B, Copland A P, Frye J W. The esophageal microbiome in health and disease[J]. Curr Gastroenterol Rep, 2018, 20(8):39.
[8] May M, Abrams J A. Emerging insights into the esophageal microbiome[J]. Curr Treat Options Gastroenterol, 2018, 16(1):72-85.
[9] Lundell L R, Dent J, Bennett J R, et al. Endoscopic assessment of esophagitis:clinical and functional correlates and further validation of the Los Angeles classification[J].Gut, 1999, 45(2):172-180.
[10] Yang L, Lu X, Nossa C W, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome[J].Gastroenterology, 2009, 137(2):588-597.
[11] Schiavi E, Gleinser M, Molloy E, et al. The surface-associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses[J].Appl Environ Microbiol, 2016, 82(24):7185-7196.
[12] MacSharry J, O'Mahony C, Shalaby K H, et al. Immunomodulatory effects of feeding with Bifidobacterium longum on allergen-induced lung inflammation in the mouse[J]. Pulmonary Pharmaco Therapeut, 2012, 25(4):325-334.
[13] Capurso L. Thirty years of lactobacillus rhamnosus GG:a review[J].J Clin Gastroenterol, 2019, 53(Suppl 1):S1-S41.
[14] Mogna L, Deidda F, Nicola S, et al. In vitro inhibition of Klebsiela pneumoniae by Lactobacilus delbruecki Subsp. delbruecki LDD01(DSM 22106):An Innovative Strategy to Possibly Counteract Such infections in humans?[J]. J Clin Gastroenterol, 2016, 50(Suppl 2):S136-S139.
[15] Ho K Y, Chan Y H, Kang J Y. Increasing trend of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country[J].Am J Gastroenterol, 2005, 100:1923-1928.
[16] Zou D, He J, Ma X, et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis:the systematic investigation of gastrointestinal diseases in China (SILC)[J].Scand J Gastroenterol, 2011, 46(2):133-141.
[17] Ashktorab H, Entezari O, Nouraie M, et al. Helicobacter pylori protection against reflux esophagitis[J].Dig Dis Sci, 2012, 57(11):2924-2928.